LEADERSHIP

Mark Sulkowski, MD; Director

Kim Kafka, BSN, RN; Program Manager; Research Nurse Manager, CRUs

Stephanie Swords, MA, CCRP; COVID Research Operations Administrator

DEPUTY DIRECTORS

Kelly Dooley, MD, MPH, PhD

David Hager, MD, PhD

STEERING COMMITTEE

William Nelson, MD, PhD, Chair

Andrea Cox, MD, PhD

Daniel Ford, MD, MPH

Elizabeth Jaffee, MD

Sumati Murli, PhD

Antony Rosen, MB, ChB, MS

Richard Rothman, MD, PhD

Lauren Sauer, MS

Megan Singleton, JD, MBE, CIP

Jeremy Sugarman, MA, MD, MPH

Mark Sulkowski, MD

David Thomas, MD, MPH

RATIONALE FOR COORDINATING COVID-19 CLINICAL RESEARCH

• Risks to patients, study participants, and staff during the pandemic.
• Patients with COVID-19 presenting to hospitals and facilities across the Johns Hopkins Health System are being cared for by newly formed clinical teams.
• Enhance research participation across the health system to inform the development of evidence-based means of treating COVID-19.
• Not overwhelm patients with multiple requests regarding research participation.
• The need to be sensitive to rapidly emerging data (interventions and the contours of the pandemic).
• The opportunity to learn from different expertise.
• Limits to the number of treatment trials we can support in terms of the number of patients with COVID-19 that meet inclusion/exclusion criteria and resources needed to open, maintain and successfully complete clinical trials.
• Our commitment that patients participate in research that is likely to yield interpretable results.
• Prioritize which protocols will receive university support, including review by the IRB.
• Prioritize supplies for non-essential resources such as PPE and reagent or specimen collection and transfer materials.
• Use resources efficiently.